These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12102698)

  • 21. Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.
    Booth N; Jula A; Aronen P; Kaila M; Klaukka T; Kukkonen-Harjula K; Reunanen A; Rissanen P; Sintonen H; Mäkelä M
    BMC Health Serv Res; 2007 Oct; 7():172. PubMed ID: 17958883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost effectiveness of hypertension treatment in Sweden.
    Johannesson M
    Pharmacoeconomics; 1995 Mar; 7(3):242-50. PubMed ID: 10155314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of impedance cardiography testing in uncontrolled hypertension.
    Ferrario CM; Smith RD;
    Am Heart Hosp J; 2006; 4(4):279-89. PubMed ID: 17086009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.
    Chen RS; Lapuerta P
    Curr Hypertens Rep; 2000 Dec; 2(6):525-9. PubMed ID: 11062597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of pharmacologic costs in the treatment of arterial hypertension. Approximation to a cost-effectiveness study].
    Alonso Moreno FJ; García Palencia M; Laborda Peralta M; Hermoso López A; Lopez de Castro F
    Aten Primaria; 1998 May; 21(9):607-12. PubMed ID: 9677744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of cost-effectiveness analyses of hypertension treatment.
    Johannesson M; Jönsson B
    Pharmacoeconomics; 1992 Apr; 1(4):250-64. PubMed ID: 10147016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.
    Zhou YF; Liu N; Wang P; Jeong Yang J; Song XY; Pan XF; Zhang X; He M; Li H; Gao YT; Xiang YB; Wu T; Yu D; Pan A
    Hypertension; 2020 Sep; 76(3):750-758. PubMed ID: 32713271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD.
    Am J Manag Care; 1998 Dec; 4(12 Suppl):S765-9; discussion S770. PubMed ID: 10339108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertensive therapy: how to evaluate the benefits.
    Zanchetti A
    Am J Cardiol; 1997 May; 79(10A):3-8; discussion 47-8. PubMed ID: 9186060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic considerations in the management of hypertension.
    Pardell H; Tresserras R; Armario P; Hernández del Rey R
    Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a computer-based decision support system for treatment of hypertension with drugs: retrospective, nonintervention testing of cost and guideline adherence.
    Persson M; Mjörndal T; Carlberg B; Bohlin J; Lindholm LH
    J Intern Med; 2000 Jan; 247(1):87-93. PubMed ID: 10672135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis in the treatment of hypertension: a medical view.
    Whitworth J; Lang D; Henry D
    Clin Exp Hypertens; 1999; 21(5-6):999-1008. PubMed ID: 10423120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials.
    Johannesson M
    Med Decis Making; 1994; 14(3):236-44. PubMed ID: 7934710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment.
    van Schoonhoven AV; van Asselt ADI; Tomaszewski M; Patel P; Khunti K; Gupta P; Postma MJ
    Hypertension; 2018 Nov; 72(5):1117-1124. PubMed ID: 30354817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension.
    Peñaloza-Ramos MC; Jowett S; Sutton AJ; McManus RJ; Barton P
    Value Health; 2018 Mar; 21(3):351-363. PubMed ID: 29566843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is cost-effectiveness analysis?
    Evans DB
    Med J Aust; 1990 Aug; 153(S1):S7-9. PubMed ID: 2116585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of innovation for hematologic malignancies.
    Monia M
    J Med Econ; 2016; 19(5):487-9. PubMed ID: 26706602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling stroke management: a qualitative review of cost-effectiveness analyses.
    Guilhaume C; Saragoussi D; Cochran J; François C; Toumi M
    Eur J Health Econ; 2010 Aug; 11(4):419-26. PubMed ID: 20238137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis and capital costs.
    Karlsson G; Johannesson M
    Soc Sci Med; 1998 May; 46(9):1183-91. PubMed ID: 9572608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Description of costs and effectiveness of a hypertension control program in primary care].
    Bonet Plá A; Alastrué Loscos I; Giner Valero M; Navarro Pérez J; Hortoneda Giménez M; Tejero Catalá MC
    Aten Primaria; 1998 Nov; 22(8):497-504. PubMed ID: 9866257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.